Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.
| -0.345 | |
| 0.655 | |
| - | |
| -0.025 | |
| 0.645 | |
| 0.11-0.25 | |
| 22 975 K | |
| 148 M | |
| 9 751 K | |
| -0.0109 | |
| 1.276 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 01 nov. 2019 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSXV:...
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 17 oct. 2019 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TS...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
